June 2013
Volume 54, Issue 15
Free
ARVO Annual Meeting Abstract  |   June 2013
Nanoparticle polyethylenimine-BMP7 Transfection Dose, Anti-fibrotic Efficacy and Toxicity for the Rabbit Cornea
Author Affiliations & Notes
  • Chaitasi Naik
    University of Missouri - Columbia/Mason Eye Institue, Columbia, MO
  • Jason Rodier
    University of Missouri - Columbia/Mason Eye Institue, Columbia, MO
  • Ajay Sharma
    University of Missouri - Columbia/Mason Eye Institue, Columbia, MO
  • Audra Stallard
    University of Missouri - Columbia/Mason Eye Institue, Columbia, MO
  • Ashish Tandon
    University of Missouri - Columbia/Mason Eye Institue, Columbia, MO
  • Alexander Klibanov
    Massachusetts Institute of Technology, Cambridge, MA
  • Rajiv Mohan
    University of Missouri - Columbia/Mason Eye Institue, Columbia, MO
  • Footnotes
    Commercial Relationships Chaitasi Naik, None; Jason Rodier, None; Ajay Sharma, None; Audra Stallard, None; Ashish Tandon, None; Alexander Klibanov, None; Rajiv Mohan, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2013, Vol.54, 4701. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Chaitasi Naik, Jason Rodier, Ajay Sharma, Audra Stallard, Ashish Tandon, Alexander Klibanov, Rajiv Mohan; Nanoparticle polyethylenimine-BMP7 Transfection Dose, Anti-fibrotic Efficacy and Toxicity for the Rabbit Cornea. Invest. Ophthalmol. Vis. Sci. 2013;54(15):4701. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: The goals of study were to characterize polyethylenimine-DNA nanoparticles (NP) transfection dose to achieve high transgene delivery at low toxicity in the cornea manipulating polyethylenimine nitrogen (N) and plasmid phosphate (P) molar ratio using an in vitro model; and, test NP-BMP7 (bone morphogenic protein 7) gene therapy potency and safety to treat corneal scarring in vivo using a rabbit model.

Methods: New Zealand white rabbits and human corneal fibroblasts (HCF) generated from donor human cornea were used. NP polyplexes with N/P molar ratio 4, 8, 15, 30 and 60 were prepared using 22kD linear polyethylenimine and plasmid encoding GFP or BMP7 gene. Time- and dose-dependent transfection assays were performed for optimization studies. Corneal fibrosis (haze) in rabbit was produced with excimer laser performing -9D photorefractive keratectomy (PRK). NP-BMP7 was topically applied on rabbit eye with custom technique for 5 minutes after PRK. Slitlamp biomicroscopy in live rabbits graded haze and ocular toxicity. Rabbits corneas were collected 4-weeks after PRK. Phase-contrast microscopy, trypan blue, MTT, TUNEL assays analyzed cellular morphology, proliferation, viability and apoptosis death. Real-time PCR, western blotting, and immunfluorescence quantified gene delivery, efficacy and toxicity.

Results: The NP-DNA gene transfer efficacy depended on N/P ratio. Higher N/P ratio in NP-DNA solution showed higher transgene delivery (40-55%, p<0.001). The N/P molar ratios >30 showed no-to-mild phenotype, proliferation or viability loss in vitro (5-13%). The transfection with N/P 8 or 15 showed low toxicity. A single 5 minutes topical NP-BMP7 (N/P 8) treatment showed significantly less corneal haze (47-53%, p<0.01) without ocular toxicity in rabbits in vivo. Further, this treatment significantly decreased mRNA (2-5 fold; p<0.01-0.001) and protein (41-56%; p<0.05-0.001) expression of 4 pro-fibrotic genes (alpha smooth muscle action, f-actin, fibronectin and collagen-1). The toxicity investigations using CD11b, F4/80 and TUNEL immunocytochemistry in rabbit tissues are underway.

Conclusions: Tested nanoparticles are safe and potent for treating corneal disorders in vivo. Targeted NP-BMP7 gene delivery has potential to treat corneal scarring in vivo. More animal and mechanistic studies are warranted.

Keywords: 484 cornea: stroma and keratocytes • 538 gene transfer/gene therapy • 607 nanotechnology  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×